In adults with type 2 diabetes, gastrointestinal adverse events were more frequent in the semaglutide arms (73% and 80%) than in the arms without semaglutide (60% and 69%).
In plain wordsIn adults with type 2 diabetes, stomach and bowel side effects were more common with semaglutide than without it.
- Peptide
- Semaglutide
- Outcome
- IncreaseGastrointestinal adverse events
- Study
n = 61
- Comparator
- Arms without semaglutide
- Outcome group
- Gastrointestinal adverse events · Gastrointestinal
- Studied dose
- 0·25 mg then 0·50 mg once per week · subcutaneous · 14 weeksAs given in this study (human).
Measurements
- GI adverse events
- 73%
- semaglutide plus placebo
- GI adverse events
- 80%
- semaglutide plus GIP
- GI adverse events
- 60%
- placebo plus placebo
- GI adverse events
- 69%
- placebo plus GIP
Source sentences
Gastrointestinal adverse events were more frequent with semaglutide (nine [60%] with placebo plus placebo, 11 [69%] with placebo plus GIP, 11 [73%] with semaglutide plus placebo, and 12 [80%] with semaglutide plus GIP).
2 context sentences(design, population, supporting numbers)
This single-centre, double-blind, parallel-group, randomised, placebo-controlled trial was conducted at the Center for Clinical Metabolic Research (Hellerup, Denmark).
Participants were randomly assigned (1:1:1:1), using a block randomisation list, to receive either placebo plus placebo, placebo plus GIP, semaglutide plus placebo, or semaglutide plus GIP (all self-administered subcutaneously).